Skip to Content
Merck
  • Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder.

Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder.

Journal of microencapsulation (2014-08-05)
Abdul Bari, Naveen Chella, Krishna Sanka, Nalini R Shastri, Prakash V Diwan
ABSTRACT

The objective of the present study was to improve solubility, dissolution rate and therapeutic efficacy of a BCS Class II drug, glibenclamide by using oral self nano emulsifying powder. The powder was prepared by adsorbing the mixture of oil, surfactant and co-surfactant onto a carrier with large surface area; Aerosil 200. The ratios of oil and Smix (surfactant/co-surfactant mixture) required to produce an emulsion was optimized based on percentage transmittance studies and particle size determinations. The optimized formulation was subjected to in vitro dissolution study and in vivo therapeutic efficacy in rabbits by monitoring blood glucose levels. Scanning electron microscopy, differential scanning calorimetry and X-ray powder diffraction studies revealed that the drug was present in amorphous form in the final formulation. The in vivo study in rabbits indicated the improved therapeutic efficacy of glibenclamide in self-nanoemulsifying powder compared to plain drug.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Isopropyl myristate, ≥90% (GC)
Sigma-Aldrich
N,N′-Disuccinimidyl carbonate, ≥95%
Sigma-Aldrich
Isopropyl myristate, ≥98%
Sigma-Aldrich
Isopropyl myristate, 98%
Sigma-Aldrich
Oleic acid, technical grade, 90%
Sigma-Aldrich
Oleic acid, ≥99% (GC)
Sigma-Aldrich
Oleic acid, BioReagent, suitable for cell culture
Sigma-Aldrich
Oleic acid, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Sigma-Aldrich
Oleic acid, natural, FCC
Sigma-Aldrich
Oleic acid, SAJ first grade, ≥70.0%